The Medical Letter on Drugs and Therapeutics
Erenumab (Aimovig) for Migraine Prevention
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The FDA has approved erenumab-aooe (Aimovig – Amgen/Novartis), a once-monthly, subcutaneously-injected, monoclonal antibody against the calcitonin gene-related peptide receptor, for preventive treatment of migraine in adults. It is the first drug in its class to be approved by the FDA.

MIGRAINE PREVENTION — Patients with frequent or severe disabling migraine headaches and those who cannot take or are refractory to acute treatment should receive preventive treatment.1,2

Beta blockers and antiepileptic drugs are commonly used for prevention of migraine, but some patients find their adverse effects difficult to tolerate. Propranolol (Inderal LA, and others) and timolol are the only beta blockers that are FDA-approved for this indication, but metoprolol (Lopressor, and others), nadolol (Corgard, and generics), and atenolol ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Erenumab (Aimovig) for Migraine Prevention
Article code: 1549b
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian